Intravenous epoprostenol therapy in the treatment of pulmonary arterial hypertension in Singapore.

The article discusses the use of intravenous epoprostenol therapy in treating pulmonary arterial hypertension (PAH) in Singapore. The study involved 12 patients, predominantly female, with a mean age of 44 years. The therapy was generally well-tolerated, with common side effects being diarrhea, headaches, and musculoskeletal complaints. The study highlights the challenges and issues faced in initiating and maintaining IV epoprostenol therapy, emphasizing the need for multidisciplinary support for patients. [Extracted from the article]